Bile, bacteria and bowel cancer
The large bowel is one of the commonest sites of carcinogenesis in western populations; it is the commonest site in the United States, West Germany, Australia, and New Zealand and is the second commonest in England and Wales, Sweden, Denmark and many other west European countries. It is, however, rare in Africa, Asia and South America and studies of migrants, religious subgroups and the like, indicated that the disease has an environmental aetiology. Most epidemiologists agree that diet is important in the causation of the disease although there is little agreement concerning which specific dietary item is most strongly implicated. This lack of agreement probably indicates that the relation between diet and colorectal carcinogenesis is not simple and is probably mediated by some factor, the concentration of which is in turn determined by diet. Aries et all postulated that colorectal cancer is caused by metabolites produced in the colon from some benign substrate by the bacterial flora. As the diet would control both the concentration of substrate and the composition and metabolic activity of the flora, it would determine the amount of metabolite; this would explain both the fact that the risk of colorectal cancer is related to diet and that the relationship is far from simple.
In following up this hypothesis most investigators have pursued the suggestion2 3 that the substrates are the bile acids. The liver synthesises two bile acids (cholic and chenodeoxycholic acids) and they are secreted as conjugates with glycine, or taurine. These are extensively metabolised by the colonic bacterial flora. with 3000 per 100 000 in humans. Consequently powerful organ specific carcinogens must be used to initiate the disease. The carcinogens used -for example, azoxymethane or dimethylhydrazine -are not likely to be experienced by humans and so it is necessary to assume that the colorectal cancers arising in rodents treated with these agents behave similarly to those arising in humans. Reddyl0 has shown that when the carcinogen used was azoxymethane, citrus pectin protected against colon carcinogenesis, but when 3,2'-dimethyl-4-aminobiphenyl was used citrus pectin had no effect to either on the proportion of animals with tumours, or on the number of tumours per animal. Similarly, germ-free status offers some protection against the colon carcinogenesis intitiated by dimethylhydrazine, but not against that initiated by MNNG. Thus the behaviour of the disease in this model apparently depends on the initiator used. In addition, the histopathology depends on the strain of rodent, as well as on the initiators and so whereas Deschner and her coworkers are clearly working with a model which mimics human colorectal cancer in showing an adenoma carcinoma sequence,11 others are using a model in which carcinomas arise de novo with no benign precursors.12 In these circumstances, interpretation of the results obtained using this animal model must be treated with considerable caution.
Because of the reservations that many workers have concerning the animal data and because of the relative cheapness of in vitro systems, many have turned to microbial mutagenicity tests such as the Ames test. 13 In such in vitro tests bile acids have been shown to be non-mutagenic, but deoxycholic and lithocolic acids have been shown to be co-mutagenic; for example, mixtures of bile acids with known mutagens give more mutations than recorded with the mutagen alone.14 15 In addition, lithocholic acid has been shown to be mutagenic in the mouse embryo mutation test.16 It is important to remember, however, that for a mutagen to be a carcinogen it must first be able to reach the target cell and in so doing overcome the various host defence mechanisms. It must then react in the target cell as it does in the mutagenesis assay and the transformed cell must then escape removal by any immune defence mechanism and fail to be repaired by any of the DNA repair mechanisms of the host. For this reason there is a tendency to treat the results of in vitro test systems with considerable reservation. Indeed, one of the virtues of these systems is that their distance from the human situation is sufficiently obvious to make it easier to resist excessive interpretation of the results.
Research in humans is very much more difficult to carry out than is work on animal models, or using in vitro systems. Furthermore, superficially it might appear that human experiments are more difficult to interpret (involving for example genetically heterogeneous populations). They are also controlled by different ethical considerations which make, for example, carcinogenicity testing impossible. Studies of aetiology in humans, however, have clear advantages over animal, or in vitro studies which more than outweigh the disadvantages. These have been listed many times elsewhere in the context of the study of carcinogenesis or other disease states. While animal models are invaluable in -for examplestudies of treatment, there is no substitute for human study in determining the causation of disease. For this reason it is gratifying to note that there has been a recent increase in the number of studies of human colorectal carcinogenesis.
Among the most important studies of human colorectal carcinogenesis are the histopathological observations which established the existence of a polyp cancer sequence, then refined it to the dysplasia carcinoma sequence.17 These observations not only gave an insight into the causation of colorectal cancer, but should also make us examine critically many of the animal models in which carcinomas clearly arise de novo. In the dysplasia carcinoma sequence all colorectal cancers arise in preformed adenomas, or other areas of mild dysplasia. There is thus a multistage process in carcinogenesis involving formation of areas of mild dysplasia (usually an adenoma), followed by increases in the area and in the severity of dysplasia and ultimately in neoplasia. The growth in the area of dysplasia and the increase in its severity are different processes, but an increase in size makes an increase in the severity of dysplasia more likely.
Early studies of the role of bile acids in large bowel cancer in humans were limited to epidemiological studies comparing populations at various levels of risk. Almost all of these reports supports a role for bile acids in bowel carcinogenesis (Table) . Case control studies comparing the faecal Studies of the benign adenoma have indicated more clearly a relation with bile acids, possibly because there have been fewer such studies. Reddy et al '9 showed that the faecal bile acid concentration in adenoma patients was higher than in controls and a relation between adenoma size and faecal bile acid concentration has also been shown.6 Van der Werf et al20 showed increased bile acid turnover and colonic absorption of deoxycholic acid in adenoma patients, compared with age-matched controls. In this issue (pp 876-880) the same group have expanded their study and have shown that not only is the colonic exposure to bile acids greater than normal in adenoma patients, but also the ratio of anaerobic to aerobic bacteria in the faeces of adenoma patients was higher.
No single study of this type is going to provide the final answer to the cause of colorectal cancer. Nevertheless, such studies on humans make an important contribution to our knowledge of colorectal carcinogenesis. They are building a picture which strongly indicates a role for bile acids and bacteria in the causation of colorectal cancer, possibly through their effect in stimulating the growth of small size benign adenomas with a low risk of malignancy, to a large size with a correspondingly high risk of malignancy. At present there is no evidence that bile acids can cause the formation of the precursor adenoma, but they may also be implicated in causing an increase in the severity of dysplasia. This is a much clearer picture of colorectal carcinogenesis and helps to explain the lack of agreement in the case control studies. Unfortunately, it also indicated that simple solutions to the prevention of the disease are not likely to be very effective. 
